Aria Pharmaceuticals will transition from drug discovery partnerships to advancing its own novel therapies in an expanding pipeline across 18 different therapeutic programs.

Both TXR-1208 and TXR-1210 demonstrated significant decrease in kidney fibrosis and inflammation compared to TGFbeta mAb, the standard metric for positive efficacy.

In vivo screening supports TRX-611 and TRX-612 as potential treatment candidates just weeks after program initiation.

In validation studies, TRX-311 demonstrated greater activity and selectivity in killing HCC tumor cells than standard of care, sorafenib, and significantly inhibited growth in two HCC patient-derived xenograft (PDX) tumor models. TRX-311 also demonstrated in vivo efficacy comparable to sorafenib with good tolerability.

Howard Rosen is a Veteran Pharmaceutical Leader and has Held Senior Positions at Some of the World's Top Pharmaceutical Companies.

Novel leads were identified in four weeks through twoXAR's proprietary AI platform and then evaluated through in vivo screening.

Dr. Eller is an accomplished pharmaceutical industry executive who brings 30 years of R&D experience. Dr. Pandey is a leader in the pharmaceutical industry bringing 25 years of experience in all stages of drug discovery and development.

The partnership combines shared drug discovery expertise with integrated AI to identify promising targets in half the time of traditional R&D approaches.

Allen’s experience forging strategic alliances in the life sciences industry will be a tremendous asset to twoXAR as the company continues to partner with leading biopharmaceutical companies to discover and develop first-in-class treatments for a wide range of diseases.

SK Biopharmaceuticals, a pharmaceutical company focused on disorders of central nervous system and cancer, and twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced an agreement to discover and develop first-in-class therapeutics for non-small cell lung cancer (NSCLC).